Longer-term results from the BENEFIT trial show sustained minimal residual disease negativity in newly diagnosed, transplant-ineligible multiple myeloma.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/can-isa-vrd-sustain-multiple-myeloma-minimal-residual-2026a10000f6?src=rss
Author :
Publish date : 2026-01-07 07:40:00
Copyright for syndicated content belongs to the linked Source.
